Here are the 424B prospectus supplements from Rallybio Corporation (RLYB) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow RLYB and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RLYB filings page.
Rallybio Corporation is seeking approval for its proposed merger with Avenzo, with registration covering approximately 193,644,387 Rallybio common shares and options to purchase 19,136,431 shares, before the proposed reverse stock split. Avenzo would survive as a wholly owned subsidiary, and Rallybio would take the name Avenzo Therapeutics, Inc. The assumed exchange ratio is 0.5020, subject to adjustment based on Rallybio Net Cash and shares outstanding at closing.
Avenzo agreed to sell shares for an aggregate purchase price of $215.0 million immediately before the merger’s effective time, subject to closing conditions. After closing, pre-merger Avenzo equityholders other than financing investors are expected to own 56.6% of the combined company, Rallybio’s pre-merger equityholders 2.8%, and financing investors 40.6%; these fully diluted estimates assume $215.0 million in financing and are subject to adjustment.
Rallybio calculated net cash of approximately $82.2 million as of August 15, 2026, and intends to distribute substantially all of it to pre-closing stockholders under the merger agreement. Only one distribution may be declared before the stockholder meeting, capped at $50 million in aggregate. The merger is conditioned on approval of three stockholder proposals and Nasdaq listing confirmation; the annual meeting is scheduled for November 4, 2026.